PCM
COCH icon

Prelude Capital Management’s Envoy Medical COCH Stock Holding History

Prelude Capital Management’s Portfolio COCH Stock Details COCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,629
Closed -$153K – 1622
2022
Q2 		$153K Hold
15,629
– – ﹤0.01% 1346
2022
Q1 		$153K Hold
15,629
– – ﹤0.01% 1322
2021
Q4 		$152K Hold
15,629
– – ﹤0.01% 1634
2021
Q3 		$152K Hold
15,629
– – ﹤0.01% 1429
2021
Q2 		$152K Buy
+15,629
New +$152K ﹤0.01% 1415

Other funds holding COCH

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

Prelude Capital Management's COCH Position: Q3 2022 in Review

Prelude Capital Management sold out of Envoy Medical (COCH) in Q3 2022, closing a stake of 15,629 shares — an estimated $153K sold.

Prelude Capital Management first reported a position in COCH in Q2 2021 and held it in 5 quarters. The position peaked at $153K in Q2 2022. 94 funds tracked by Wall St. Rank hold COCH as of Q3 2022.

  • Prelude Capital Management reported no remaining Envoy Medical position as of Q3 2022 after selling out during the quarter.
  • Prelude Capital Management sold 15,629 Envoy Medical shares in Q3 2022, an estimated $153K.
  • Prelude Capital Management first reported a position in Envoy Medical in Q2 2021 and held it in 5 quarters.
  • Prelude Capital Management's Envoy Medical position peaked at $153K in Q2 2022.
  • 94 funds tracked by Wall St. Rank held Envoy Medical as of Q3 2022.

Based on Prelude Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.